Children’s National Health System touted data today from a Phase I dose-ranging study evaluating a cell therapy approach in patients with blood and bone marrow cancers for whom stem cell transplantation hasn’t worked.
Results from the Resolve trial showed that 78% of patients responded to multi-tumor-associated antigen specific lymphocytes (TAA-L) treatment and 44% of patients had complete remission with limited toxicity, according to Children’s National.
Get the full story at our sister site, Drug Delivery Business News.
The post Children’s National Health System highlights novel approach for cell therapy appeared first on MassDevice.
from MassDevice http://ift.tt/2l3Kjq3
Cap comentari:
Publica un comentari a l'entrada